Facebook
Twitter
Telegram
Report an ErrorCyclerion Therapeutics Financial Ratios 2011-2024 | CYCN
Annual Financial Ratios Cyclerion Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-1.3 | -0.0 | -0.8 | -1.3 | -0.8 | - | - | - | - | - | - | - | - |
P/S |
- | 3.8 | 10.4 | 44.2 | 20.7 | - | - | - | - | - | - | - | - |
EPS |
-2.2 | -20.3 | -1.3 | -2.6 | -4.5 | -4.2 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
-791 K | -12.3 M | -12.9 M | 103 M | 86.9 M | 17.8 M | 14 M | - | - | - | - | - | - |
EBITDA per Share |
- | -8.5 | -1.4 | -2.46 | -4.47 | - | - | - | - | - | - | - | - |
EV/EBITDA |
0.3 | -0.6 | 0.0 | - | - | - | - | - | - | - | - | ||
PEG |
- | -0.03 | 0.12 | - | - | - | - | - | - | - | - | ||
P/B |
0.5 | 0.1 | 0.7 | 1.7 | 1.0 | - | - | - | - | - | - | - | - |
P/CF |
-0.3 | -0.0 | -1.1 | -1.4 | -0.9 | - | - | - | - | - | - | - | - |
ROE % |
-46.62 | -421.72 | -107.05 | -130.78 | -125.87 | - | - | - | - | - | - | - | - |
ROA % |
-39.35 | -243.81 | -87.05 | -67.43 | -65.96 | - | - | - | - | - | - | - | - |
ROCE % |
-114.73 | -177.38 | -114.40 | -82.56 | -74.33 | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | - | 3.5 | 5.5 | - | - | - | - | - | - | - | - |
DSO |
- | 120.4 | 4.6 | 20.2 | 119.4 | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 120.4 | 4.6 | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | 120.4 | 4.6 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Cyclerion Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
3.11 | -1.83 | - | - | -4.83 | -6.16 | -0.3 | - | -0.26 | -0.45 | -0.39 | - | -0.59 | -0.7 | -0.73 | - | -1 | -1.18 | -1.37 | - | -1.07 | -1.09 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | - | - | -2.05 | -6.15 | -0.3 | - | -0.25 | -0.44 | -0.39 | - | -0.66 | -0.69 | -0.72 | - | -1 | -1.18 | -1.35 K | - | -1.06 K | -1.07 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-263.10 | -385.40 | -357.00 | -151.35 | -171.38 | -127.88 | -99.90 | -72.50 | -104.12 | -115.72 | -123.74 | -98.46 | -126.41 | -122.74 | -122.91 | -99.20 | 181.18 | 489.51 | 807.64 | 807.56 | 807.56 | 527.18 | 242.06 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-33.57 | -125.20 | -121.81 | -107.81 | -124.48 | -99.25 | -82.59 | -51.44 | -67.74 | -67.38 | -62.94 | -50.77 | -65.42 | -63.76 | -64.13 | -51.99 | -447.69 | -828.75 | -1213.84 | -1139.71 | -1139.71 | -744.01 | -341.62 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-156.46 | -137.07 | -107.65 | -115.37 | -135.38 | -128.05 | -99.89 | -72.47 | -109.08 | -125.68 | -133.94 | -104.28 | -132.95 | -125.01 | -125.76 | -100.74 | 179.64 | 488.69 | 807.64 | 807.56 | 807.56 | 527.18 | 242.06 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | 67.7 | 21.0 | - | 20.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | 67.7 | 21.0 | - | 20.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | 67.7 | 21.0 | - | 20.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency